Arvinas, Inc. (ARVN)Healthcare | Biotechnology | New Haven, United States | NasdaqGS
11.00 USD
After hours: 11.22 +0.22 (2.000%) ⇧ (April 17, 2026, 7:09 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:54 p.m. EDT
ARVN is a high-risk stock with a negative earnings outlook and poor fundamentals. The stock has been volatile, with recent dips and rallies. While there is some short-term momentum, it is not strong enough to justify a buy recommendation. The lack of dividends and the high overall risk make it unsuitable for long-term investors. Short-term traders should be cautious and consider the high volatility and mixed options signals before entering any trades. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.117621 |
| AutoETS | 0.119807 |
| AutoARIMA | 0.121692 |
| AutoTheta | 0.144405 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 7.66 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.150 |
| Excess Kurtosis | -1.40 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.051 |
| Revenue per Share | 3.704 |
| Market Cap | 706,467,264 |
| Forward P/E | -3.12 |
| Beta | 1.98 |
| Profit Margins | -30.77% |
| Website | https://www.arvinas.com |
As of April 11, 2026, 3:54 p.m. EDT: Options speculators are showing mixed signals. The current price is near the 52-week low, but there is some call and put activity around the current price, indicating potential for both upward and downward movement. The high IV for near-term expirations suggests increased volatility, which could be due to earnings reports or market sentiment. However, the overall options activity does not show a clear consensus on the direction of the stock, making it a risky short-term play.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2571429 |
| Address1 | 5 Science Park |
| Address2 | 395 Winchester Avenue |
| All Time High | 108.47 |
| All Time Low | 5.9 |
| Ask | 11.03 |
| Ask Size | 2 |
| Audit Risk | 3 |
| Average Analyst Rating | 2.2 - Buy |
| Average Daily Volume10 Day | 810,350 |
| Average Daily Volume3 Month | 858,637 |
| Average Volume | 858,637 |
| Average Volume10Days | 810,350 |
| Beta | 1.976 |
| Bid | 10.94 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 6.833 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.0 |
| Current Ratio | 4.917 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 11.34 |
| Day Low | 10.97 |
| Debt To Equity | 2.051 |
| Display Name | Arvinas |
| Earnings Call Timestamp End | 1,771,938,000 |
| Earnings Call Timestamp Start | 1,771,938,000 |
| Earnings Timestamp | 1,771,939,800 |
| Earnings Timestamp End | 1,777,552,200 |
| Earnings Timestamp Start | 1,777,552,200 |
| Ebitda | -111,900,000 |
| Ebitda Margins | -0.42611998 |
| Enterprise To Ebitda | -0.242 |
| Enterprise To Revenue | 0.103 |
| Enterprise Value | 27,070,968 |
| Eps Current Year | -3.50704 |
| Eps Forward | -3.52375 |
| Eps Trailing Twelve Months | -1.14 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.0142 |
| Fifty Day Average Change | -1.0142002 |
| Fifty Day Average Change Percent | -0.08441679 |
| Fifty Two Week Change Percent | 25.71429 |
| Fifty Two Week High | 14.51 |
| Fifty Two Week High Change | -3.5100002 |
| Fifty Two Week High Change Percent | -0.24190214 |
| Fifty Two Week Low | 5.9 |
| Fifty Two Week Low Change | 5.1 |
| Fifty Two Week Low Change Percent | 0.86440676 |
| Fifty Two Week Range | 5.9 - 14.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,538,055,000,000 |
| Float Shares | 55,345,451 |
| Forward Eps | -3.52375 |
| Forward P E | -3.1216743 |
| Free Cashflow | -89,012,496 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 246 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.0 |
| Gross Profits | 262,600,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08180001 |
| Held Percent Institutions | 0.86730003 |
| Implied Shares Outstanding | 64,224,294 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. |
| Long Name | Arvinas, Inc. |
| Market | us_market |
| Market Cap | 706,467,264 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_243040896 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -80,800,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 703,251,162 |
| Number Of Analyst Opinions | 16 |
| Open | 11.21 |
| Operating Cashflow | -273,800,000 |
| Operating Margins | -7.54737 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 203 535 1456 |
| Post Market Change | 0.22000027 |
| Post Market Change Percent | 2.0000024 |
| Post Market Price | 11.22 |
| Post Market Time | 1,776,467,381 |
| Previous Close | 11.0 |
| Price Eps Current Year | -3.1365483 |
| Price Hint | 2 |
| Price To Book | 1.6098346 |
| Price To Sales Trailing12 Months | 2.690279 |
| Profit Margins | -0.30769 |
| Quick Ratio | 4.855 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.15789 |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 11.34 |
| Regular Market Day Low | 10.97 |
| Regular Market Day Range | 10.97 - 11.34 |
| Regular Market Open | 11.21 |
| Regular Market Previous Close | 11.0 |
| Regular Market Price | 11.0 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 758,990 |
| Return On Assets | -0.079380006 |
| Return On Equity | -0.16231 |
| Revenue Growth | -0.84 |
| Revenue Per Share | 3.704 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 63,960,997 |
| Shares Percent Shares Out | 0.0705 |
| Shares Short | 4,506,829 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,292,094 |
| Short Name | Arvinas, Inc. |
| Short Percent Of Float | 0.0718 |
| Short Ratio | 5.18 |
| Source Interval | 15 |
| State | CT |
| Symbol | ARVN |
| Target High Price | 21.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 14.875 |
| Target Median Price | 15.5 |
| Total Cash | 685,400,000 |
| Total Cash Per Share | 10.716 |
| Total Debt | 8,900,000 |
| Total Revenue | 262,600,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.14 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.30545 |
| Two Hundred Day Average Change | 0.69454956 |
| Two Hundred Day Average Change Percent | 0.067396335 |
| Type Disp | Equity |
| Volume | 758,990 |
| Website | https://www.arvinas.com |
| Zip | 6,511 |